Correlation Between Cadrenal Therapeutics, and Nuvectis Pharma

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Nuvectis Pharma, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Nuvectis Pharma.

Diversification Opportunities for Cadrenal Therapeutics, and Nuvectis Pharma

0.6

Correlation Coefficient

Cadrenal Therapeutics,  Nuvectis Pharma

Poor diversification

The 3 months correlation between Cadrenal and Nuvectis is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Nuvectis Pharma go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Nuvectis Pharma

Given the investment horizon of 90 days Cadrenal Therapeutics, is expected to generate 2.53 times less return on investment than Nuvectis Pharma. But when comparing it to its historical volatility, Cadrenal Therapeutics, Common is 1.27 times less risky than Nuvectis Pharma. It trades about 0.12 of its potential returns per unit of risk. Nuvectis Pharma is currently generating about 0.23 of returns per unit of risk over similar time horizon. If you would invest  514.00  in Nuvectis Pharma on December 30, 2024 and sell it today you would earn a total of  532.00  from holding Nuvectis Pharma or generate 103.5% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Nuvectis Pharma

Cadrenal Therapeutics,

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Nuvectis Pharma

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Nuvectis Pharma are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating fundamental indicators, Nuvectis Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Cadrenal Therapeutics, and Nuvectis Pharma

The main advantage of trading using opposite Cadrenal Therapeutics, and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.

The idea behind Cadrenal Therapeutics, Common and Nuvectis Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.